Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

Autor: Rachel A. Freedman, Lisa A. Carey, Harvey J. Cohen, Jacqueline Lafky, Ann H. Partridge, Jared C. Foster, Jeanne S. Mandelblatt, Clifford A. Hudis, Alvaro Moreno-Aspitia, Eric P. Winer, C. Cirrincione, Arti Hurria, Drew K. Seisler, Hyman B. Muss, Aminah Jatoi, Gretchen Kimmick

Publikováno v: Journal of Clinical Oncology. 35:421-431

Purpose Despite increasing awareness of accrual challenges, it is unknown if accrual of older patients to breast cancer treatment trials is improving. Methods We examined accrual of older patients to Alliance for Clinical Trials in Oncology systemic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62a0bc65995d72c9e9a39cc7c658f403
https://doi.org/10.1200/jco.2016.69.4182

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

Autor: Linda Sutton, Lynn G. Dressler, Patricia A. Kartcheske, Julie R. Gralow, Aminah Jatoi, Ronald D. Hart, Heshan Liu, Maria Theodoulou, Alice B. Kornblith, C. Cirrincione, Barbara A. Parker, Ann M. Mauer, Edith A. Perez, Ahmad A. Mahmood, Arti Hurria, Mei Yin C. Polley, Debjani Grenier, Donald A. Berry, Lisa A. Carey, Larry Norton, Hyman B. Muss, Clifford A. Hudis, Gustav Magrinat, Harold J. Burstein, Harvey J. Cohen, Eric P. Winer, Ann H. Partridge, Antonio C. Wolff

PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78d83708f8da175563c5bd878d26f78
https://europepmc.org/articles/PMC6900836/

Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

Autor: Elisa R. Port, Deborah Collyar, R Qamar, Jennifer R. Bellon, Sara M. Tolaney, EP Winer, William M. Sikov, K Sturtz, Lisa A. Carey, CM Perou, C. Cirrincione, George Somlo, Olwen Hahn, Baljit Singh, Clifford A. Hudis, Eleftherios P. Mamounas, Mehra Golshan, Donald A. Berry

Publikováno v: Cancer Research. 76:S2-05

Background: CALGB (Alliance) 40603 measured the effects of adding carboplatin (Cb) and/or bevacizumab (Bev) to standard neoadjuvant chemotherapy (weekly paclitaxel x 12 then doxorubicin/cyclophosphamide every 2 weeks x 4) on pathologic complete respo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65d3cfcc3d870190c93999de9b54cee6
https://doi.org/10.1158/1538-7445.sabcs15-s2-05

Corrosion inhibition of iron in acidic solution by a green formulation derived from Nigella sativa L

Autor: A. Srhiri, N. Bettach, Maria Pia Casaletto, Najat Hajjaji, Hamid Erramli, C. Cirrincione, Mohamed Chellouli, Antonella Privitera, Driss Chebabe, A. Dermaj

Publikováno v: Electrochimica acta 204 (2016): 50–59. doi:10.1016/j.electacta.2016.04.015
info:cnr-pdr/source/autori:Chellouli M.; Chebabe D.; Dermaj A.; Erramli H.; Bettach N.; Hajjaji N.; Casaletto M.P.; Cirrincione C.; Privitera A.; Srhiri A./titolo:Corrosion inhibition of iron in acidic solution by a green formulation derived from Nigella sativa L./doi:10.1016%2Fj.electacta.2016.04.015/rivista:Electrochimica acta/anno:2016/pagina_da:50/pagina_a:59/intervallo_pagine:50–59/volume:204

In this work the corrosion inhibition of iron in acidic solution by a formulation based on the oil extracted from the seeds of Nigella Sativa L. (labeled as FBN) was investigated by means of potentiodynamic polarization, electrochemical impedance spe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddf7c2d8e055b849e2592bdea06a002e
http://www.cnr.it/prodotto/i/361679

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840

Autor: Eric P. Winer, Harvey J. Cohen, Clifford A. Hudis, Stuart M. Lichtman, Andrew D. Seidman, Hyman B. Muss, C. Cirrincione, Arti Hurria

Publikováno v: Annals of Oncology. 23:632-638

Two Cancer and Leukemia Group B (CALGB) studies were utilized to determine the efficacy and tolerability of paclitaxel (Taxol) in older patients with metastatic breast cancer.CALGB 9840 evaluated weekly paclitaxel (80 mg/m(2)) versus paclitaxel every

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1419616f1f6b23dafbacbabb29c3e9cb
https://doi.org/10.1093/annonc/mdr297